Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine, Cisplatin, and Docetaxel in Advanced NSCLC
NCT00004264Phase 2Unknown
- Sponsor
- University of Wisconsin–Madison
- Start
- Jul 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in non-small cell lung cancer (NSCLC), sponsored by University of Wisconsin–Madison. Primary endpoints: Maximum Tolerated Dose, Response Rate and 2 more. Status: unknown.
02
Drugs
amifostine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00004264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004264.